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Tyrosine hydroxylase is activated inPC-12 cells by bradykinin in a concentration-dependent manner with maximal stimu- 
lation occurring at 1 PM. This stimulatory effect occurs within 15 s and is maximal at 5 min. This stimulation is due 
to an increase in the affinity of tyrosine hydroxylase for its pterin cofactor, and can be blocked by a specific bradykinin 
receptor antagonist. These data indicate that bradykinin can regulate the activity of tyrosine hydroxylase in PC- I2 cells. 
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1. INTRODUCTION 
Tyrosine hydroxylase is the rate-limiting enzyme 
in the pathway concerned with the biosynthesis of 
catecholamines in both the central and peripheral 
nervous systems [1,2]. Numerous studies have 
shown that the activity of tyrosine hydroxylase can 
be increased in rat pheochromocytoma PC-12 cells 
in situ by depolarization with high potassium or 
treatments with dibutyryl cyclic AMP, calcium 
ionophore and phorbol esters [3-61. Recently, 
Calker and Heuman [7] reported that treatment of 
PC-12 cells with bradykinin, a putative central ner- 
vous system neurotransmitter [8,9], increased the 
accumulation of inositol- 1,4,5trisphosphate 
(IP3), suggesting that PC-12 Ce]]S contain receptors 
that respond to bradykinin. Here, we have ana- 
lyzed the effects of bradykinin on tyrosine hydrox- 
ylase activity in PC-12 cells. 
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2. MATERIALS AND METHODS 
2.1. CeN culture 
The PC-12 cells were subcultured on 35-mm polylysine- 
treated dishes at a density of 1 x IO6 cells/dish in RPM1 1640 
medium supplemented with 10% heat-inactivated horse serum, 
5% fetal bovine serum, streptomycin (50 &ml) and penicillin 
(50 U/ml). After 3 days in culture, cells were washed twice with 
oxygenated pre-warmed (37°C) Krebs-Ringer-Hepes buffer 
(KRH buffer), pH 7.4, containing 125 mM NaCl, 4.8 mM KCI, 
2.6 mM CaC12, 1.2 mM MgSO+ 25 mM Hepes and 5.6 mM 
glucose. The cells were preincubated with KRH buffer at 37°C 
for 15 min prior to treatment with bradykinin. 
2.2. Assay of tyrosine hydroxylase activity 
After incubation, KRH buffer was removed and cells were 
immediately frozen on dry ice and scraped into a solution con- 
taining 30 mM potassium phosphate buffer (pH 6.8). 50 mM 
NaF and 1 mM EDTA. The suspension was homogenized, the 
homogenate being centrifuged at 2OOOOxg for 10 min. The 
supernatant was collected and subjected to gel filtration on a 
Sephadex G-50 column equilibrated with 30 mM potassium 
phosphate buffer (pH 6.8), 10 mM NaF and 0.1 mM EDTA. 
Tyrosine hydroxylase activity was determined by a modification 
of the coupled decarboxylase assay [IO]. The standard incuba- 
tion medium consisted of 100 mM potassium phosphate buffer 
(pH 6.8), 5 mM ascorbic acid, 6500 U catalase, 5 mM EDTA, 
0.2 mM L-2-amino-4-hydroxy-6-methyl-5,6,7,8,-tetrahydro- 
pteridine-HCI (6-MePtH4, Calbiochem-Behring), 0.1 mM (0.1 
uCi) L-[I-“‘Cltyrosine and 65 pl supernatant enzyme (final 
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volume, 100 ~1). The reaction was terminated following a 10 
min incubation at 30°C by addition of 5 mM 3-iodotyrosine in 
50 mM potassium phosphate buffer (pH 6.8). The [I-%]dihy- 
droxyphenylalanine produced in the above reaction was decar- 
boxylated by further incubation of the assay tubes for 30 min 
at 37°C following addition of partially purified hog kidney L- 
aromatic amino acid decarboxylase and pyridoxal phosphate. 
The reaction was then terminated by addition of 0.1 ml of 0.8 
M perchloric acid. The ‘%ZOz liberated was collected in wells 
containing 0.2 ml NCS tissue solubilizer (Amersham), and the 
wells were transferred to counting vials. Radioactivity was 
determined by liquid scintillation spectrometry. Protein content 
was measured by the method of Bradford [Ill with bovine 
serum albumin as the standard. Tyrosine hydroxylase activity 
was expressed as nmol 14C02 formed/min per mg protein. 
3. RESULTS AND DISCUSSION 
The time course for the activation of tyrosine 
hydroxylase by bradykinin is shown in fig.1. 
Tyrosine hydroxylase activity was significantly in- 
creased in PC-12 cells following incubation with 
10e6 M bradykinin for 15 s. Maximal activation of 
tyrosine hydroxylase occurred after a 5 min in- 
cubation with bradykinin (460%), and the enzyme 
remained activated at 10 min (3800/o). 
Bradykinin (lo-* M) significantly increased 
tyrosine hydroxylase activity in PC-12 cells (fig.2). 
Maximal activation of the enzyme was achieved at 
10m6 M bradykinin. The median effective concen- 
tration (EGO) of bradykinin for the activation of 
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Fig.1. Time course of the effects of bradykinin on tyrosine 
hydroxylase activity in PC-12 cells. PC-12 cells were incubated 
at 37°C for different time intervals in the presence or absence 
of 10e6 M bradykinin. Tyrosine hydroxylase activity was 
determined as described in section 2. Data are means + SE 
from 5-7 experiments. Bradykinin significantly increased 
tyrosine hydroxylase activity greater than control values at all 
time points. 
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Fig.2. Effects of different concentrations of bradykinin on 
tyrosine hydroxylase activity. PC-12 cells were incubated for 5 
min in the presence or absence of varying concentrations of 
bradykinin. Tyrosine hydroxylase activity was determined as 
described in section 2. Data are means + SE from 5-7 
experiments. Concentrations of bradykinin between 10e8 and 
1O-4 M are significantly greater than the 0 concentration. 
tyrosine hydroxylase was approx. 3 x 10T7 M. This 
concentration of bradykinin is similar to that 
necessary to produce an approx. 400% increase in 
formation of inositol phosphates in PC-12 cells 
[71. 
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Fig.3. Inhibition of bradykinin-induced activation of tyrosine 
hydroxylase by bradykinin antagonist. The cells were incubated 
for 5 min in the presence or absence of bradykinin. The 
bradykinin antagonist, [D-Argo]-Hyp3-This*s-[D-Phe’]-brady- 
kinin, was added 5 min before bradykinin addition. Tyrosine 
hydroxylase activity was determined as described in section 2. 
Data are means + SE from 5-7 experiments. Concentrations of 
[D-Argo]-Hyp3-Thi’*s-[D-Phe’]-bradykinin between lo-’ and 
lo-’ M significantly inhibit bradykinin-induced activation of 
tyrosine hydroxylase. 
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Fig.4. Kinetic analysis of the effect of bradykinin on tyrosine hydroxylase activity at various cofactor concentrations. The cells were 
incubated for 5 min in the presence or absence of 10m6 M bradykinin. Tyrosine hydroxylase activity was determined as described in 
section 2. All values were determined at 0.1 mM L-[1-?]tyrosine. Data are means k SE from 3-5 experiments. 
bradykinin antagonist, [D-Arg”]-Hyp3-ThiS*8-[D- 
Phe’]-bradykinin (a gift from R.J. Vavrek and 
J.M. Stewart, University of Colorado Health 
Sciences Center) on bradykinin-stimulated tyrosine 
hydroxylase activity. Bradykinin-stimulated 
tyrosine hydroxylase activity was inhibited at all 
concentrations of the antagonist tested with max- 
imal inhibition occurring at lo-’ M (68%). 
Fig.4 illustrates the kinetic analysis of the activa- 
tion of tyrosine hydroxylase by 10m6 M 
bradykinin. Bradykinin produced a significant 
decrease in the K,,, of tyrosine hydroxylase for the 
pterin cofactor with no change in V,,,. The kinetic 
values were Km 1.56kO.21 mM and V,,,,, 3.7 kO.4 
nmol/min per mg protein for control and Km 
0.26 kO.04 mM and V,,,,, 4.4 f 0.6 nmol/min per 
mg protein for bradykinin. 
Bradykinin may activate tyrosine hydroxylase by 
two potential mechanisms in PC-12 cells. Incuba- 
tion of PC-12 cells with bradykinin produces an in- 
crease in IP3 and presumably in diacylglycerol [7]. 
IP3 has been shown to release Ca2+ from in- 
tracellular stores in many tissues [ 121. Increasing 
Ca2+ intracellularly in the PC-12 cells may 
stimulate tyrosine hydroxylase by activating 
calcium/calmodulin-dependent protein kinase, 
which in the presence of an activator protein is 
known to activate and phosphorylate tyrosine 
hydroxylase [ 131. In addition, diacylglycerol has 
also been shown to stimulate protein kinase C ac- 
tivity [14], which has also been shown to activate 
and phosphorylate tyrosine hydroxylase [6,15-171. 
Therefore, the activation of tyrosine hydroxylase 
by bradykinin may be the result of an increase in 
activity of calcium/calmodulin-dependent protein 
kinase and/or protein kinase C leading to a direct 
phosphorylation and activation of tyrosine 
hydroxylase. We are presently evaluating the ef- 
fects of bradykinin on the phosphorylation of 
tyrosine hydroxylase in PC-12 cells. 
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